Eighteen chronic schizophrenic patients received subcutaneous doses of apomorphine, a dopamine receptor agonist, and of placebo in separate trials. A significant improvement in psychotic symptoms occurred after apomorphine compared to placebo. The results are interpreted as a consequence of presynaptic dopamine receptor activation by apomorphine with a subsequent decrease in dopamine-mediated neural transmission.
No takes yet. Share an insight, caveat, or question.
Tamminga et al. (1978) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: